Saturday 17 October 2026
Export ELVN’s income statement to Excel — free account
Enliven Therapeutics, Inc.
ELVN Healthcare Biotechnology
In the quarter to June 2026, EPS was flat and free cash flow fell 8.34%, each against the same quarter a year earlier.
37.32
2.01
−5.11%
Follow ELVN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (15.31%) | (26.64%) | (26.95%) | (25.43%) |
+8 more TTM periods Free account |
|
| (14.98%) | (25.74%) | (25.86%) | (24.41%) | ||
ROIC |
0.00% | (7,507.00%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(11.86%) | (21.87%) | (22.62%) | (20.75%) | |
Free Cash Flow per Share |
(1.01) | (1.04) | (1.24) | (1.16) | |
Free Cash Flow |
(66.96) | (65.46) | (70.25) | (71.82) | |
Capital Expenditures |
(0.02) | — | 0.06 | (0.16) | |
| Other line items | |||||
Cash ROIC |
(3.74%) | (7.23%) | (7.62%) | (7.53%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.63 | 0.66 | 0.68 | 0.74 | |
Depreciation/Fixed assets |
4.65 | 14.35 | 1.06 | 2.48 | |
Capex/Depreciation |
(0.04) | 0.00 | 1.53 | (0.16) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.01) | (1.04) | (1.24) | (1.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates